In conclusion, the expression of Plk1 and Plk4 in pediatric B-ALL patients was significantly higher compared to healthy blood donors and Plk1-targeting siRNNs induced a Plk1 specific and significant knockdown in each treated patient sample. Here, PLK4 is linked to precursor B-cell acute lymphoblastic leukemia.